A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta.

Saved in:
Bibliographic Details
Title: A pan-variant mRNA-LNP T cell vaccine protects HLA transgenic mice from mortality after infection with SARS-CoV-2 Beta.
Authors: Carter B; Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.; Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, United States., Huang P; Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States., Liu G; Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.; Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, United States., Liang Y; Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States., Lin PJC; Acuitas Therapeutics, Vancouver, BC, Canada., Peng BH; Department of Neuroscience, Cell Biology, and Anatomy, The University of Texas Medical Branch, Galveston, TX, United States., McKay LGA; National Emerging Infectious Diseases Laboratories, Department of Microbiology, Boston University School of Medicine, Boston, MA, United States., Dimitrakakis A; Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.; Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, United States., Hsu J; Department of Neuroscience, Cell Biology, and Anatomy, The University of Texas Medical Branch, Galveston, TX, United States., Tat V; Department of Pathology, The University of Texas Medical Branch, Galveston, TX, United States., Saenkham-Huntsinger P; Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States., Chen J; Department of Biomedical Engineering, Tufts University, Medford, MA, United States., Kaseke C; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States., Gaiha GD; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States.; Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, United States., Xu Q; Department of Biomedical Engineering, Tufts University, Medford, MA, United States., Griffiths A; National Emerging Infectious Diseases Laboratories, Department of Microbiology, Boston University School of Medicine, Boston, MA, United States., Tam YK; Acuitas Therapeutics, Vancouver, BC, Canada., Tseng CK; Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, United States.; Department of Neuroscience, Cell Biology, and Anatomy, The University of Texas Medical Branch, Galveston, TX, United States.; Department of Pathology, The University of Texas Medical Branch, Galveston, TX, United States., Gifford DK; Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA, United States.; Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, United States.; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, United States.
Source: Frontiers in immunology [Front Immunol] 2023 Mar 09; Vol. 14, pp. 1135815. Date of Electronic Publication: 2023 Mar 09 (Print Publication: 2023).
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1664-3224
DOI:10.3389/fimmu.2023.1135815